Jyong Biotech Ltd. (NasdaqGM: MENS)
Health Care · Biotechnology · TW
$2.10
-3.67% today · -95.8% 1Y
Jyong Biotech Ltd. (NasdaqGM: MENS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $161.83M and employs 27 people.
Over the last twelve months the share price has lost 95.8%, trading between 1.43 and 63.00.
Tweenvest scores Jyong Biotech Ltd. across four factors: quality 11/100, value 38/100. Its strongest factor is value.
MENS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $161.83M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.06
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $63.00
- 52-week low
- $1.43
- Avg volume (3M)
- —
- Shares outstanding
- 74.23M
- Employees
- 27
- Next earnings
- —
About Jyong Biotech Ltd.
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
- ISIN
- KYG831161065
- Founded
- 2002
- Listed since
- Jun 17, 2025
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ALX Oncology Holdings Inc.NasdaqGS: ALXO | $163.17M | $1.18 | +4.42% |
| AptaBio Therapeutics Inc.KOSDAQ: A293780 | $162.71M | ₩7,800.00 | +20.74% |
| GC Cell CorporationKOSDAQ: A144510 | $162.68M | ₩14,580.00 | +3.77% |
| Cue Biopharma, Inc.NasdaqCM: CUE | $162.21M | $22.33 | -0.80% |
| HLB Therapeutics Co.,Ltd.KOSDAQ: A115450 | $161.65M | ₩2,470.00 | +24.31% |
| BNC KOREA, Inc.KOSDAQ: A256840 | $160.23M | ₩3,155.00 | +19.73% |
| Protara Therapeutics, Inc.NasdaqGM: TARA | $159.56M | $2.65 | -1.85% |
| NovaBridge BiosciencesNasdaqGM: NBP | $158.92M | $1.37 | 0.00% |
Figures last refreshed Oct 4, 2026.